Adamax
Aliases: Adamantane-Semax · N-acetyl-Semax-adamantyl
Last verified: 2026-09-24
The short version
Adamax is a pure distillation of the gray market: take an existing peptide with a real reputation (Semax is a registered drug in Russia), add an exotic chemical group, weave a story about 'CNS penetration' and sell at a premium. The problem: no independent lab has confirmed that what is sold is what is claimed, no study has measured any of the promises, and adamantane acylation changes peptide immunogenicity — in ways nobody has mapped. This is a substance whose only 'evidence' is the vial label.
Identity & type
- Molecular type
- analog
- Origin
- Claimed to be acetylated Semax with an adamantane group; adamantane is a rigid hydrocarbon cage that increases lipophilicity.
Mechanism of action
Per vendor description: acetylated Semax with an adamantane modification, designed to prolong action and CNS penetration; the Semax base acts on melanocortin receptors and BDNF/NGF expression. None of the modifications have been characterized in peer-reviewed literature.
not confirmed in humans
Dosing & routes
Official / clinical context
No official context exists — in no country, in no database.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Most often intranasally in the morning ('clarity, focus'), 2–4 week cycles; some users report a stimulant-like effect similar to strong caffeine, others nothing. No published measurements.
Unverified self-reports. Not medical advice. Not endorsement.
Protocol — official vs community
Official / label
No approved product. N-acetyl Semax amidate — a community-engineered Semax derivative with zero formal human data.
Duration: —
Every protocol for Adamax is an extrapolation from Semax's domestic Russian labeling.
Community (anecdotal)
Nasal spray 100–300 mcg 1–2× daily.
- Cycle:
- 2 weeks on, 2 weeks off (Semax rhythm inherited).
- Break:
- 2 weeks.
The amidate modification is asserted (not demonstrated) to improve stability and CNS penetration.
Human evidence
None for Adamax. The Semax base has limited Russian data — that is all that exists in human proximity to this substance.
Preclinical evidence
Not a single Adamax study has been published. The mechanistic rationale leans on Semax and general adamantane pharmacology.
Known risks
- Unknown identity/purity — analytical confirmation of structure is often absentcharacterized
- Sleep disturbance and agitation with longer usecharacterized
- Immunogenicity of the modified peptide is untestedtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Practically everything — structure, pharmacokinetics, effect
- Whether 'Adamax' even contains adamantane
Frequently asked questions
References
- No peer-reviewed studies of Adamax identified (as of last verification)
- Semax clinical literature (Russian neurological practice) — base compound only